CytoMed Therapeutics Limited
CytoMed Therapeutics Limited (GDTC) Revenue
Annual & quarterly revenue history · segment & region breakdown
GDTC · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCytoMed Therapeutics Limited trailing twelve-month (TTM) revenue is $0.00B, an increase of 359.28% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | +359.28% |
| 2024-12-31 | $0.00B | -$0.00B | -86.35% |
| 2023-12-31 | $0.00B | +$0.00B | +39.26% |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income CytoMed Therapeutics Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
CytoMed Therapeutics Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in SGD.
Data sourced from CytoMed Therapeutics Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
GDTC revenue · 4 questionsGDTC's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 359.28% year-over-year from $0.00B in FY2025.
▸ Source: FMP · CytoMed Therapeutics Limited SEC filings · GAAP · CytoMed Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026